Tiapride attenuates pain transmission through an indirect activation of central serotonergic mechanism.
Tiapride dose-dependently attenuated the biphasic nociceptive responses induced by s.c. injection of formalin to the hindpaw of mice, and its activity on the first (ED50 = 110 mg/kg p.o.) and the second (ED50 = 32.0 mg/kg p.o.) phases paralleled that on the nociceptive response to intrathecal injection of substance P (ED50 = 190 mg/kg p.o.) and somatostatin (ED50 = 56.0 mg/kg p.o.), respectively. Moreover, a similar antinociceptive activity was observed in streptozotocin-induced diabetic or genetically diabetic (db/db) mice. The effects of tiapride (100 mg/kg p.o.) on both phases of the formalin test in normal mice were abolished by pretreatment with p-chlorophenylalanine (800 x 2 mg/kg p.o.), a 5-hydroxytryptamine (5-HT) depletor, or pindolol (1 mg/kg i.p.), a 5-HT1 antagonist, but were scarcely affected by 3-tropanyl-indole-3-carboxylate, a 5-HT3 antagonist. Ketanserin (1 mg/kg i.p.), a 5-HT2 antagonist, attenuated the effect of tiapride on the second phase but not on the first phase. This study on the antinociceptive mechanism of action of tiapride (that blocks painful neuropathy in diabetic patients) has led us to hypothesize that the drug attenuates pain transmission through an indirect activation of central 5-HT1 and 5-HT2 receptors.
Takeshita
N
N
Basic Research Group, Tsukuba Research Laboratories, Fujisawa Pharmaceutical Co. Ltd., Ibaraki, Japan.
Ohkubo
Y
Y
Yamaguchi
I
I
D000818:Animals; D002490:Central Nervous System / Q000502:physiology*; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000503:physiopathology; D018492:Dopamine Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology*; D005260:Female; D010134:Fenclonine / Q000031:analogs & derivatives; D007211:Indoles; D007278:Injections, Spinal; D007650:Ketanserin; D008297:Male; D051379:Mice; D009619:Nociceptors / Q000187:drug effects* / Q000502:physiology*; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D010147:Pain Measurement / Q000187:drug effects; D010869:Pindolol; D012701:Serotonin / Q000502:physiology*; D012702:Serotonin Antagonists; D013004:Somatostatin; D013373:Substance P; D009435:Synaptic Transmission / Q000187:drug effects*; D013976:Tiapamil Hydrochloride / Q000493:pharmacokinetics / Q000494:pharmacology*; D000077526:Tropisetron
D018492:Dopamine Antagonists; D007211:Indoles; D012702:Serotonin Antagonists; C020261:4-chlorophenylalanine methyl ester; D012701:Serotonin; D013373:Substance P; D013004:Somatostatin; D000077526:Tropisetron; D007650:Ketanserin; D010869:Pindolol; D010134:Fenclonine; D013976:Tiapamil Hydrochloride